The Technical Analyst
INmune Bio Inc [INMB]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
INmune Bio Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-4.89% $8.37
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 152.36 mill |
| EPS: | -1.670 |
| P/E: | -5.01 |
| Earnings Date: | May 01, 2024 |
| SharesOutstanding: | 18.20 mill |
| Avg Daily Volume: | 0.0874 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Buy | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.01 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.85x |
| Company: PE -5.01 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$1.304 (-84.43%) $-7.07 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 7.59 - 9.15 ( +/- 9.33%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-11-10 | Juda Scott | Buy | 7 000 | Common Stock |
| 2023-07-12 | Schroeder Timothy J | Sell | 10 000 | Common Stock |
| 2023-03-17 | Moss David J | Buy | 2 500 | Common Stock |
| 2023-02-16 | Tesi Raymond Joseph | Buy | 160 000 | Option (right to buy) |
| 2023-02-16 | Juda Scott | Buy | 35 000 | Option (right to buy) |
| INSIDER POWER |
|---|
| 94.49 |
| Last 100 transactions |
| Buy: 4 257 822 | Sell: 701 956 |
Forecast:
16:00 - $8.37
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $8.37
Forecast 2: 16:00 - $8.37
Forecast 3: 16:00 - $8.37
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $8.37 (-4.89% ) |
| Volume | 0.0688 mill |
| Avg. Vol. | 0.0874 mill |
| % of Avg. Vol | 78.70 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For INMB
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 14 - 14:15 | buy | $14.50 | N/A | Active |
|---|
INMB
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Latest Press Releases
2024-04-08 08:00:00 - Press Release
Inmune Bio Inc. Presents Data On Inb03's Role As An Immune Check Point Modulator In The Treatment Of High-risk Breast Cancer At Aacr 2024
Novel immunotherapy approach targets soluble tumor necrosis factor to overcome resistance and enhance therapeutic outcome in high-risk breast cancer
2024-03-28 16:01:00 - Press Release
Inmune Bio Inc. Announces Year End 2023 Results And Provides A Q4 Business Update
Boca raton, fla., march 28, 2024 (globe newswire) -- inmune bio inc. (nasdaq: inmb) (the “company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announces its financial results for the year ended december 31, 2023 and provides a business update.
2024-03-26 16:01:00 - Press Release
Inmune Bio Inc. To Report Fourth Quarter 2023 Financial Results And Provide A Corporate Update On Thursday, March 28
Management to host conference call and webcast at 4:30 pm et on that day boca raton, florida, march 26, 2024 (globe newswire) -- inmune bio inc. (nasdaq: inmb) (the “company”), a clinical-stage immunology and inflammation company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on thursday, march 28, 2024 at 4:30 pm eastern time to discuss results for its fourth quarter ended december 31, 2023 and to provide a corporate update. conference call information to participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
2024-03-13 08:00:00 - Press Release
Inmune Bio Cso And Co-founder Mark Lowdell, Ph.d. Receives The Isct Career Achievement Award In Cell And Gene Therapy
International society for cell & gene therapy (isct) names dr. lowdell with the career achievement award in cell and gene therapy recognizing exceptional contributions and achievements in the field boca raton, florida, march 13, 2024 (globe newswire) -- inmune bio inc. (nasdaq: inmb) (the “company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, announces its chief scientific officer and co-founder mark lowdell, ph.d. has been awarded the career achievement award in cell and gene therapy by the international society of cell & gene therapy (isct), which the organization considers its highest honor.
2024-03-05 08:00:00 - Press Release
Inmune Bio Reports Significant Eeg Improvement In Alzheimer's Patients Treated With Xpro™
Patients with alzheimer's disease show improvement in brainwaves following 4 weeks of xpro™ therapy.
Latest News
2024-03-28 20:18:07 - Seeking Alpha
INmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcript
2024-02-06 09:00:00 - GlobeNewsWire
INmune Bio to Participate in Baird's Biotech Discovery Series Webcast on February 13, 2024
Boca Raton, Florida, Feb. 06, 2024 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer's disease (AD) with XProTM (XPro1595; pegipanermin), a dominant-negative inhibitor of soluble TNF, announces its management will be participating in Baird's Biotech Discovery Series webcast on Tuesday, February 13, 2024 at 10:30AM EST. The webcast will feature RJ Tesi, MD, CEO, CJ Barnum, PhD, head of Neuroscience, and Malu Tansey, PhD, Professor of Neuroscience and Neurology, Norman and Susan Fixel Chair in Parkinson's Disease, Director, Parkinson's Foundation Research Center of Excellence, University of Florida.
2023-12-05 03:58:10 - Seeking Alpha
Alzheimer's Disease Drug Development: Another Lost Year
Investing in most current Alzheimer's drug companies is not recommended because they are not likely to modify the disease. Compounds that inhibit oxidative stress may only slow down the progression of Alzheimer's disease over the short term. Anavex's blarcamesine, Cyclo Therapeutics Trappsol Cyclo, Green Valley's GV-971, aromatherapy, and panax ginseng not only inhibit the formation of oxidants but scavenge them and reverse part of their damage.
2023-11-05 20:28:17 - InvestorPlace
7 Earnings Losers to Load Up On Right Now
Generally speaking, earnings losers represent exactly that – companies that failed to deliver against established targets. Just like in sports, you don't get points for missing the shot or not going over the endzone.
2023-11-01 22:38:08 - Seeking Alpha
INmune Bio, Inc. (INMB) Q3 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Joel Beatty - Baird Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Greetings and welcome to the INmune Bio Third Quarter 2023 Earnings Call. At this time, all participants are in a listen-only mode.
2023-07-31 08:00:00 - GlobeNewsWire
INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, July 31, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Monday, August 7, 2023 at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2023 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.
2023-06-02 14:26:00 - Proactive Investors
INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say
Analysts at Baird initiated coverage of the immunology company INmune Bio with a price target more than double its current share price. The firm issued an Outperform rating and target price of $16.
2023-05-24 09:00:00 - GlobeNewsWire
INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy
BOCA RATON, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) announces that Mark Lowdell, Ph.D., INmune Bio's CSO, will be giving the opening plenary lecture of the Presidential Symposium at the International Society of Cell and Gene Therapy (ISCT) in Paris, France on May 31st.
2023-05-03 22:00:20 - Seeking Alpha
INmune Bio, Inc. (INMB) Q1 2023 Earnings Call Transcript
INmune Bio, Inc. (NASDAQ:INMB ) Q1 2023 Earnings Conference Call May 3, 2023 4:30 PM ET Company Participants David Moss - Chief Financial Officer RJ Tesi - Chief Executive Officer Mark Lowdell - Chief Scientific Officer Conference Call Participants Tom Shrader - BTIG Daniel Carlson - Tailwinds Research Operator Good day and welcome to the INmune Bio First Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode.
2023-04-24 09:00:00 - GlobeNewsWire
INmune Bio, Inc. to Report First Quarter 2023 Financial Results and Provide a Corporate Update on Wednesday, May 3
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 24, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness a patient's innate immune system to fight disease, today announced that it will host a conference call on Wednesday, May 3, 2023 at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2023 and to provide a corporate update. Conference Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call.